State Street SSGA美国股票溢价盈余主动型ETF SPIN 深 沪
已收盘 05-08 16:00:00 美东时间
32.00
0.000
0.00%
华盛通- 最 高32.06
- 今 开32.02
- 成交量 9619股
- 最 低 32.00
- 昨 收 32.00
- 总市值 4608.00万
- 52周最高 32.4194
- 市盈率 静 --
- 换手率 0.67%
- 52周最低 26.5532
- 委 比 0.00%
- 总股本 144.00万
- 历史最高 32.4194
- 量 比 0.56
- 振 幅 0.19%
- 历史最低 22.7113
- 每 手 1
- 风险率 1.63%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Flex Q4 2026 Earnings Call: Complete Transcript
Flex (NASDAQ:FLEX) held its fourth-quarter earnings conference call on Wednesda...
05-06 21:29
BRIEF-OpenAI's Altman Discussed Spinning Out Co's Robotics, Consumer Hardware Divisions Late Last Year - WSJ
BRIEF-OpenAI's Altman Discussed Spinning Out Co's Robotics, Consumer Hardware Divisions Late Last Year - WSJ May 4 (Reuters) - OPENAI CHIEF EXECUTIVE SAM ALTMAN DISCUSSED SPINNING OUT THE COMPANY'S ROBOTICS AND CONSUMER HARDWARE DIVISIONS LATE LAST YEAR - WSJ PLAN TO SPIN OUT OPENAI'S ROBOTICS, CONS
05-05 09:04
AtaiBeckley Announces Expanded Phase 2a Results For EMP-01 In Adults With Social Anxiety Disorder That Demonstrate Clinically Meaningful And Consistent Improvements Across Clinician-Rated Symptoms, Patient-Reported Experience And Real-World Behavioral Outcomes
At Day 43, EMP‑01 achieved a 38% reduction vs 15% on placebo (Hedges' g=0.84) on the patient-reported Social Phobia Inventory (SPIN), a 32% reduction vs 14% on placebo on the Subtle Avoidance Frequency Examination
04-22 18:11
BRIEF-Warner Music Central Europe And Spinnin’ Records Launches Spinnin’ Records Germany
BRIEF-Warner Music Central Europe And Spinnin’ Records Launches Spinnin’ Records Germany April 10 (Reuters) - Warner Music Group Corp WMG.O : WARNER MUSIC GROUP: WARNER MUSIC CENTRAL EUROPE AND SPINNIN’ RECORDS LAUNCHES SPINNIN’ RECORDS GERMANY Further company coverage: WMG.O
04-10 17:06
BRIEF-FDA Approves New High Dose Regimen Of Spinraza® (Nusinersen) For Spinal Muscular Atrophy
BRIEF-FDA Approves New High Dose Regimen Of Spinraza® (Nusinersen) For Spinal Muscular Atrophy March 30 (Reuters) - Biogen Inc BIIB.O : FDA APPROVES NEW HIGH DOSE REGIMEN OF SPINRAZA® (NUSINERSEN) FOR SPINAL MUSCULAR ATROPHY BIOGEN - HIGH DOSE SPINRAZA TO BE AVAILABLE IN U.S. IN COMING WEEKS Source
03-30 20:01
BRIEF-Anaptys Announces $100 Million Stock Repurchase Plan And Provides A Business Update
BRIEF-Anaptys Announces $100 Million Stock Repurchase Plan And Provides A Business Update AnaptysBio Inc ANAB.O : ANAPTYS ANNOUNCES $100 MILLION STOCK REPURCHASE PLAN AND PROVIDES A BUSINESS UPDATE ANAPTYSBIO INC - TO SPIN-OFF BIOPHARMA OPERATIONS INTO FIRST TRACKS BIOTHERAPEUTICS ON APRIL 20, 2026
03-27 21:04
BRIEF-Anaptys Board Of Directors Approves Spin-Off Of First Tracks Biotherapeutics
BRIEF-Anaptys Board Of Directors Approves Spin-Off Of First Tracks Biotherapeutics AnaptysBio Inc ANAB.O : ANAPTYS BOARD OF DIRECTORS APPROVES SPIN-OFF OF FIRST TRACKS BIOTHERAPEUTICS Source text: ID:nGNX4WVKfC Further company coverage: ANAB.O
03-27 21:03
BRIEF-First Tracks Biotherapeutics, The Planned Spin-Off Of Anaptys, Secures Commitments Of $145 Million In Private Placement
BRIEF-First Tracks Biotherapeutics, The Planned Spin-Off Of Anaptys, Secures Commitments Of $145 Million In Private Placement AnaptysBio Inc ANAB.O : FIRST TRACKS BIOTHERAPEUTICS, THE PLANNED SPIN-OFF OF ANAPTYS, SECURES COMMITMENTS OF $145 MILLION IN PRIVATE PLACEMENT Source text: ID:nGNX1Ml9sl Fur
03-27 21:03
Sysmex presents fully automated plasma p-Tau205 immunoassay data at AD/PD 2026
Sysmex presents fully automated plasma p-Tau205 immunoassay data at AD/PD 2026 Sysmex reported multiple poster presentations planned for AD/PD 2026 on blood-based biomarkers for amyloid-related disease and Alzheimer’s pathology. One presentation will describe development of a fully automated plasma
03-23 08:19
BRIEF-Spinal Elements Expands Ventana® Platform With FDA 510(K) Clearance And First Cases Of Ventana® A Alif System
BRIEF-Spinal Elements Expands Ventana® Platform With FDA 510(K) Clearance And First Cases Of Ventana® A Alif System March 18 (Reuters) - Spinal Elements Holdings Inc SPEL.O : SPINAL ELEMENTS EXPANDS VENTANA® PLATFORM WITH FDA 510(K) CLEARANCE AND FIRST CASES OF VENTANA® A ALIF SYSTEM Source text: ID
03-18 20:05
